This is a working overview of GHRH analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Joe: The Rise of Cobra Jenny Slate (2004), cast member, Saturday Night Live Anna Paquin* (2004), winner of the Academy Award for The Piano Rider Strong (2004), star of Boy Meets World Julia Jones (2005), actress in The Twilight Saga and Dexter: New Blood Julia Stiles (2005), star of Save the Last Dance and Mona Lisa Smile Kate McKinnon (2006), Emmy winning actress and comedian, Saturday Night Live Grace Parra (2006), actress, screenwriter, TV host Emmy Rossum* (2008), Golden Globe-nominated actress of The Phantom of the Opera and The Day After Tomorrow Hal Scardino (2008), child actor known for his role in The Indian in the Cupboard Jeremy Blackman (2009), appeared in Magnolia Max Minghella (2009), appeared in Syriana and Art School Confidential Spencer Treat Clark (2010), appeared in Gladiator, Mystic River, and Unbreakable Asher Grodman (2010), actor, Ghosts Sarah Steele (2011), actress, Spanglish Remy Zaken (2012), actress on Spring Awakening Jin Ha (2013), actor, Love Life, Devs Devyn Tyler (2013), actress, Clarice and Snowfall Gabby Beans (2014), actress, Tony Award for Best Actress in a Play nominee Kelsey Chow (2014), actress, Pair of Kings Cinta Laura (2014), actress and singer Sofia Vassilieva (2014), actress, Eloise at the Plaza, Eloise at Christmastime Marjana Chowdhury (2015), model, actress, philanthropist and beauty queen Hari Nef (2015), transgender model, actress, and writer; signed to IMG Models Ben Platt* (2016), actor and singer, Pitch Perfect, The Book of Mormon, Dear Evan Hansen, transferred to Columbia University School of General Studies Katie Chang* (2017), actress, The Bling Ring, A Birder's Guide to Everything Timothée Chalamet* (2017), Academy Award-nominated actor, Call Me by Your Name Sami Gayle (2018), actress, Blue Bloods, Candy Jar, Vampire Academy Kenny Ridwan (2021), actor, The Goldbergs Emily Robinson (2021), actress, The Orphans' Home Cycle, Eighth Grade Kiera Allen (2022), actress, Run Peyton Elizabeth Lee (2026), actress, Andi Mack Avantika Vandanapu (2027), actress, Mean Girls
A chronic wound is a wound that does not progress through the normal stages of wound healing—hemostasis, inflammation, proliferation, and remodeling—in a predictable and timely manner. Typically, wounds that do not heal within three months are classified as chronic. Chronic wounds may remain in the inflammatory phase due to factors like infection or bacterial burden, ischaemia, presence of necrotic tissue, improper moisture balance of wound site, or underlying diseases such as diabetes mellitus. In acute wounds, a regulated balance of pro-inflammatory cytokines (signalling molecules) and proteases (enzymes) prevent the degradation of the extracellular matrix (ECM) and collagen to ensure proper wound healing. In chronic wounds, there is excessive levels of inflammatory cytokines and proteases, leading to excessive degradation of the ECM and collagen. This disrupts tissue repair and impedes recovery, keeping the wound in a non-healing state. Chronic wounds may take years to heal or, in some cases, may never heal, causing significant physical and emotional stress for patients and placing a financial burden on healthcare systems. Acute and chronic wounds are part of a spectrum, with chronic wounds requiring prolonged and complex care compared to acute wounds.
== Indications for use == Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure and a decreased need for repeated coronary artery revascularization in the first month following the procedure. Research also shows that this drug can be of use for patients with diabetes and chronic kidney disease. It is not the appropriate drug of choice if a patient is scheduled for an emergency surgery (i.e., heart surgery) because bleeding time may take about 12 hours to normalize. Pediatric uses include treatment of Kawasaki disease.
== Education and career == Bhatt graduated Boston Latin School, earned his science degree as a National Merit Scholar from MIT, an MD from Cornell and an MPH from Harvard. He received his Executive MBA from the University of Oxford in 2024. He trained in internal medicine and cardiology at the University of Pennsylvania and Cleveland Clinic, completing fellowships in interventional cardiology and cerebral and peripheral vascular intervention. He served as chief interventional fellow at Cleveland Clinic where he worked as an interventional cardiologist, associate professor of medicine, director of the interventional cardiology fellowship, associate director of the cardiovascular medicine fellowship, and associate director of the cardiovascular coordinating center. Later, he became the Chief of Cardiology at the VA Boston Healthcare System and, subsequently, the Interventional Cardiovascular Programs executive director at Brigham and Women's Hospital. Additionally, he was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. In 2012, he was appointed a professor of medicine at Harvard Medical School.
Sources: en.wikipedia.org
==== Germany ==== The Federal Office for Radiation Protection has developed a radon map of Germany. The EU Directive 2013/59/Euratom (Radiation Protection Basic Standards Directive) introduced reference levels and the possibility for workers to have their workplace tested for radon exposure. In Germany, it was implemented in the Radiation Protection Act (Chapter 2 or Sections 124-132 StrlSchG) § 124-132 StrlSchG (in German) and the amended Radiation Protection Ordinance (Part 4 Chapter 1, Sections 153-158 StrlSchV). § 153-158 Act of (in German) The new radon protection regulations for workplaces and new residential buildings have been binding since January 2019. Extensive radon contamination and radon precautionary areas have been determined by the ministries of the environment of the federal states (as of June 15, 2021).
Parmotrema perlatum has a thallus that ranges from loosely to tightly attached to the surface it grows on, forming expansive, spreading colonies that often merge together. Individual thalli typically measure up to 10–15 cm (4–6 in) in diameter. The upper thallus surface is greenish-grey, blue-grey, or yellowish-grey in colour, lacking pruina and either free of spots (maculae), or with few maculae. This species develops soredia, a type of asexual reproductive structure, aiding in its propagation. The lobes of this lichen vary from 1.5 to 10 mm in width, with a wave-like (undulate) or ruffled pattern and overlapping (imbricate) arrangement. The tips and edges of these lobes are generally smooth and round, sometimes notched (crenate) or incised, often curling up or inward, revealing the paler brown to black underside adorned with hair-like structures (cilia) up to 2.5 mm in length. Rhizines are common on the underside of the thallus, except for a brown border near the edges. The soredia found in this species are granular and appear white or may become grey due to wear. They are located within specifically structured groups called soralia, which can be linear to oval in shape, often positioned at the edges of the lobes. The presence of soredia causes the lobe margins to curl back and form capitate soralia. The upper surface of the lichen is typically whitish grey to pale greenish-grey, and can be either smooth or slightly wrinkled, without spots (immaculate), featuring scattered, shallow cracks. Isidia are absent in this species.
== Pharmacokinetics == Following single or multiple intravenous infusions, the majority of drug elimination occurred within 24 hours of intravenous administration. Elimination half-life of eteplirsen was 3 to 4 hours.
=== October === 9 October Críostóir Ó Floinn, 95, writer. Hugh Friel, 71, drummer (The Atrix). 10 October – Dónal O'Neill, 56, Gaelic footballer (Edenderry, Offaly senior team). 13 October – Hugh Russell, 63, boxer, Olympic bronze medallist (1980). 15 October – Gerry Ryan, 68, footballer (Bohemians, Derby County, Brighton, national team). 17 October – Paul Reynolds, 50, cricket umpire. 29 October – Jimmy Duggan, 93, hurler (Liam Mellows, Galway senior team, Connacht). 31 October – Séamus Leydon, 81, Gaelic footballer (Dunmore MacHales, Nemo Rangers, Galway senior team, Connacht).
One mixed-mode column can replace two or even more single mode columns, which is economic and eco-friendly for employing the stationary phase more sufficiently and reducing the consuming and ‘waste’ of raw materials. Single mixed-mode column can be applied for on-line two-dimensional (2D) analysis in a sealed system via establishing corresponding chromatographic system or off-line 2D analysis as two columns.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.